Clinical breast cancer
-
Clinical breast cancer · Jul 2017
Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer.
For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treatment of recurrent breast cancer, prompting this investigation. ⋯ NSM may be performed in carefully selected patients with recurrent breast cancer, despite prior ipsilateral surgery and radiation, with successful preservation of the nipple-areolar complex and an acceptably low complication rate. Our data suggest no short-term adverse effect of NSM on oncologic outcomes.
-
Clinical breast cancer · Jun 2017
Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
Several approaches have been suggested for incorporating risk factors to predict the future risk of breast cancer. The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and International Breast Cancer Intervention Study (IBIS) are among these approaches. We compared the performance of these models in discriminating between cases and noncases in the Iranian population. ⋯ The IBIS model discriminated cases and noncases better than the BOADICEA model in the Iranian population. However, the discrimination of the logistic regression model, which included a larger array of familial, genetic, and personal risk factors, was better than the 2 models.
-
Clinical breast cancer · Jun 2017
Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study.
Although the indication for immediate breast reconstruction (IBR) after skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) has been expanded, IBR after neoadjuvant chemotherapy (NACT) is still controversial. We conducted retrospective matched case-control study to analyze oncologic outcomes between patients who underwent TM only and those who underwent IBR after SSM or NSM after NACT. ⋯ IBR after SSM or NSM might be a feasible surgical treatment option even in breast cancer patients who underwent NACT.
-
Clinical breast cancer · Apr 2017
Disparities in Surgical Treatment of Early-Stage Breast Cancer Among Female Residents of Texas: The Role of Racial Residential Segregation.
Early-stage breast cancer can be surgically treated by using mastectomy or breast-conserving surgery and adjuvant radiotherapy, also known as breast-conserving therapy (BCT). Little is known about the association between racial residential segregation, year of diagnosis, and surgical treatment of early-stage breast cancer, and whether racial residential segregation influences the association between other demographic characteristics and disparities in surgical treatment. ⋯ Residents of areas with high indices of racial residential segregation were less likely to be treated with M/BCT. Racial disparities in treatment using M/BCT increased with increasing racial residential segregation.
-
Clinical breast cancer · Dec 2016
Randomized Controlled Trial Comparative StudyRamucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to fifth-line therapy in women with advanced breast cancer. ⋯ Ramucirumab combined with eribulin did not significantly improve PFS in advanced MBC.